Thomas W. LeBlanc, MD, MA

Panelists discuss long-term results from a phase 3 trial comparing luspatercept and epoetin alfa in lower-risk MDS, highlighting luspatercept’s superior efficacy in achieving sustained transfusion independence and the need for further research on earlier intervention strategies.

Panelists discuss the results of the phase 3 EPO-PRETAR trial in a dynamic, debate-style forum on lower-risk myelodysplastic syndromes, weighing the benefits of early vs late erythropoiesis-stimulating agent initiation while highlighting the need for more patient-centered outcome measures.

After sharing key takeaways on the management of BPDCN, expert hematologist-oncologists highlight unmet needs and forecast evolutions in care.

Before closing out their review of adverse events associated with tagraxofusp, Thomas Leblanc, MD, and Bhumika Patel, MD, reflect on the identification and management of myelosuppression.

A brief review of the role of tagraxofusp as bridging therapy to stem cell transplant in patients diagnosed with blastic plasmacytoid dendritic cell neoplasm.

Comprehensive discussion on the management of adverse events associated with tagraxofusp and how BPDCN care can be optimized in the setting of academic centers.

Centering discussion on a recent study, experts Thomas Leblanc, MD, and Bhumika Patel, MD, reflect on long-term data with tagraxofusp in BPDCN.

Expert hematologist-oncologists share their perspective on the broad diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

In this video we discuss the goals of shared-decision making in hematologic malignancies and touch upon different scenarios where its use may be appropriate.

As Dennis et al demonstrate, palliative care (PC) is a unique and multifaceted philosophy of care geared towards patients living with serious illness, not only those dying from it.